A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
Full description
Frequently people undergoing treatment for AML or MDS experience physical and emotional symptoms during the course of their illness. These can be very distressing to both patients and their caregivers. Patients with AML or MDS receiving non-intensive therapy also often experience a rapid decline in their health status and have a limited prognosis. Despite their limited life-expectancy, they rarely engage in discussion with their clinicians regarding their goals and preferences for care at the end of life. The study doctors want to know if the early introduction of a team of clinicians that specialize in the lessening (palliation) of many of these distressing symptoms and have expertise in enhancing communication about prognosis and illness trajectory may improve the overall care of patients with acute leukemia.
This team of clinicians is called the palliative care team and they focus on ways to improve the participant's pain and other symptom management (nausea, fatigue, shortness of breath, anxiety, etc.) and to assist the participant and the participant's caregivers in coping with the emotional and social issues associated with their diagnosis. The team consists of physicians and advance practice nurses who have been specially trained in the care of patients facing serious illness.
The main purpose of this study is to compare two types of care - standard oncology care and standard oncology care with collaborative involvement of palliative care clinicians to see which is better for improving the experience of patients with AML and MDS undergoing treatment.
The purpose of this research study is to find out whether introducing patients undergoing treatment for AML or MDS to the palliative care team can improve their end-of-life communication, understanding of their prognosis, and their physical and psychological symptoms during the course of their illness.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations:
- Newly diagnosed AML
- Relapsed AML
- Primary refractory AML
-
The ability to provide informed consent
-
The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter
Exclusion criteria
- Patients not receiving care at MGH
- Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization)
- Patients receiving supportive care alone
- Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures
- Patients already receiving palliative care
Trial design
Primary purpose
Allocation
Interventional model
Masking
320 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Areej El-Jawahri, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal